

Eingeladene Vorträge

Genomic platforms in Prostate Cancer – The EORTC strategy.

2nd Spanish meeting in prostate cancer-joint meeting of the Spanish Society of Radiation Oncology, Clinical Oncology and Urology, 13. May 2019, Madrid, Spain.

Diagnostic procedures in prostate cancer diagnosis: State-of-the-art ASCO-GU Direct – Highlights. Bern 2. March 2019, Bern, Schweiz.

Das lokalisierte Prostatakarzinom, PSA, Radiologie

Onkologie/Hämatologie Update Refresher Kurs. 16.– 17. November 2018, Zürich, Schweiz.

Controversies in the management of oligometastatic prostate cancer: Cytoreductive local therapy should be the first choice. Intercontinental Prostate Cancer conference 4, Saturday, 14 April 2018, Madrid, Spain.

Oligometastatic prostate cancer: Does it exist and if yes, how is it defined and is it treated? SAMO Interdisciplinary Workshop on Urogenital Tumors, 13./14. April 2018, Lucerne, Switzerland.

Oligometastatic PCa – fact or fiction? The 10th Engadin Prostate Cancer Symposium, Zuoz, Sitzerland 01. – 03. March 2018.

Challenges and opportunities for molecular driven care in prostate cancer: The EORTC SPECTA program. Heinrich Warner Symposium 2017, 22.-24.6.2017, Hamburg Germany.

Controversies in metastatic prostate cancer: Debate: Is there a role for local treatment of oligometastatic disease? Yes: M. Spahn; No: B. Tombal. The European Association of Urology, 32th Congress 2017, London, March 24.-28.2017.

Next-generation sequencing of prostate tumours: use of individualised biomarkers for prognosis and treatment. 6th International Symposium on Treatment of Prostate Cancer (STOP6), Lisbon 14-16. October 2016.

Workshop 3: Lymph node-positive surgery. 6th International Symposium on Treatment of Prostate Cancer (STOP6), Lisbon 14-16. October 2016.

Debate: 'Oligometastases: RP is experimental and should only be done in the context of a prospective clinical trial' versus 'RP and SBRT to bone disease is a reasonable management strategy.

for men with oligometas' Martin Spahn and Mack Roach. 6th International Symposium on Treatment of Prostate Cancer (STOP6), Lisbon 14-16. October 2016.

Is there a role for salvage lymphadenectomy: when and how? Global Congress on Prostate Cancer 2016, Vienna, Austria June 29.-01 July 2016.

State-of-the art: vision on the future: Urology. Global Congress on Prostate Cancer 2016, Vienna, Austria June 29.-01 July 2016.

How to diagnose and treat prostate cancer. Swiss congress of Radiology 2016, Davos, Switzerland, May 19.-21.2016.

Introduction to Cancer Treatment: The three “classical” mainstays of cancer: Surgery – Radiation – Medications > and their combinations; The 2nd EORTC Cancer Clinical Research Methodology Course for Patient Advocates, Brussels, Belgium, 4.-5.3.2016.

Treatment of localized and advanced PCa: surgery or radiotherapy? Laurence Klotz, Toronto (pro surgery: localized PCa), Martin Spahn, Berne (pro surgery: advanced PCa), Thomas Wiegel, Ulm (pro radiotherapy: localized and advanced PCa). The 9th Engadin Prostate Cancer Winter Symposium, Zuoz, Schweiz, 21-23-1.2016.

Neo-adjuvant therapy before radical prostatectomy: A re-opened chapter? Current and future role. 13th Meeting of the EAU Section of Oncological Urology, Warsaw, Poland, 15- 17.1.2016.

Contra – Neoadjuvant Chemotherapy for Bladder Cancer. SAMO Interdisciplinary Workshop on Urogenital Tumors, Luzern, Schweiz, 17.-18.4.2015.

Focal Therapies in Prostate Cancer: Which lesion to treat at all?SAMO Interdisciplinary Workshop on Urogenital Tumors, Luzern, Schweiz, 17.-18.4.2015.

Biomarkers/Translational research: Where are we?, Global Congress on Prostate Cancer, Rom, Italien, 5.-7. Februar 2015.

“Nerve Sparing Cystectomy”, Semi-Live Meeting, Heidelberg, 29-31.1.2015.

The surgical overtreatment of prostate cancer. Urological Symposium, Zürich, Schweiz, 24/25. October 2014.

Contra - Neoadjuvant Chemotherapy for bladder Cancer. FB Tag der Schweizer Gesellschaft für Urologie. Bern, Schweiz, 19.6.2014.

Master Class on the treatment of Advanced Prostate Cancer. 34th Congress of the Société Internationale d’Urologie (SIU), Glasgow, Scotland, October 12 to 15, 2014.

The SPECTAprostate concept or high-risk prostate cancer beyond retrospective data. The European Association of Urology, 29th Congress 2014, Stockholm, April 11.-15.2014.

PSA is rising after curative intended Radiotherapy: More local options? SAMO Interdisciplinary Workshop on Urogenital Tumors, Luzern, 8.-9. November 2013.

Beyond PSA: The next generation of prostate cancer biomarkers. Global Congress on Prostate Cancer, Marseille, June 12.-14.2013.

Surgery in High-Risk Prostate cancer, 106th National Congress of the French Association of Urology, Paris, November 21.-24.2012.

Diagnostik und Therapie des Prostatakarzinoms, 10. Berner Symposium Molekulare Bildgebung und Therapie, Bern 10. November 2012.

Was Man Weiß, Was Man Wissen Sollte – Prostatakarzinom, 64. Kongress der Deutschen Gesellschaft für Urologie, 26.-29.9.2012, Leipzig.

Was Man Weiß, Was Man Wissen Sollte – Prostatakarzinom, 64. Kongress der Deutschen Gesellschaft für Urologie, 26.-29.9.2012, Leipzig.

Localised Prostate Cancer. „Who needs Active Surveillance? SAMO Interdisciplinary Workshop on Urogenital Tumors, Luzern, 14.-15.9.2012.

Biomarkers: What do we have now and what might we have in the future? Global Congress on Prostate Cancer, Brussels, June 28.-30.2012.

Prostatakarzinom und Bestrahlung – Grenzen, 38. Jahrestagung der Bayerischen und der Österreichischen Gesellschaft für Urologie, Nürnberg, 14.-16.6.2012.

Highlights Prostate Disease, The European Association of Urology, 27th Congress 2012, Paris, February 24.-28.2012.

Surgery in High risk PCa, Montsouris Symposium: Update in Urology, Paris, February 23. 2012.

Harnblasenkarzinom – Systemische Therapie, Onkoforum Urologie. Aktuelles zu Diagnostik und Therapie urologischer Malignome. ASCO, AUA, EAU 2011, München 22.10.2011 und Köln, 19.11.2011.

Expertenkurs der Akademie der Deutschen Urologie „Radikale Beckenchirurgie“, 63. Kongress der Deutschen Gesellschaft für Urologie, Hamburg, 14.-17.9.2011.

Outcome predictors of radical prostatectomy in patients with prostate specific antigen greater than 20ng/ml: A European multi-institutional study of 712 patients, Joint Session of the EORTC, ESUR and ESOU, The European Association of Urology, 26th Congress 2011, Vienna, March 18-22, Translational Research and Multidisciplinary approach to urological cancers.

High risk Prostate cancer: Debate – Risk Classification, Plenary Session 2, The European Association of Urology, 26th Congress 2011, Vienna, March 18-22.

Open surgery: Will it stay forever? Course on Best Clinical Evidence for curative treatment of prostate cancer, Turin, May 7. 2010.

Prognostic Marker in High-Risk Prostate Cancer, Dept. of Urology, University of Leuven, Belgium, June 30, 2008.

Kontinente Harnableitung mit Ileozökalpouch und Nabelstoma – Langzeitergebnisse, 20. Kongress der Deutschen Kontinenzgesellschaft, Leipzig, 7-8-11-2008.

Highlights Prostatakarzinom, 57. Kongress der Deutschen Gesellschaft für Urologie, Düsseldorf 21.-24.9.2005.

15. Bayerisches Expertengespräch Urologie, Würzburg, 17.- 18.7.2009.

Unterfränkische Urologentreffen (4 CME-Zertifizierte Veranstaltungen)

Kongresssekretär 57. Jahrestagung der Deutschen Gesellschaft für Urologie, Düsseldorf

Fortbildungsveranstaltungen der Urologischen Klinik Karlsruhe (4 CME-Zertifizierte Veranstaltungen pro Jahr).

Endourologisches Symposium, Mannheim.